



May 11, 2023

To whom it may concern

Company Name Y.A.C. HOLDINGS CO., LTD.
Representative MOMOSE Takefumi
Representative Director, Chairman and
President
(Code number TSE 6298, TSE Prime)
Inquiries HATAKEYAMA Osamu
Director & General Manager, Administration
Headquarter
Tel: +81-42-546-1161

Notice Regarding Capital Alliance with LINUS BIOTECHNOLOGY, INC. (U.S.A.)

We inform that at the Board of Directors meeting held today (May 11, 2023), we resolved to enter into a capital alliance agreement with LINUS BIOTECHNOLOGY, INC. (hereafter, Linus Bio) as below.

1. Background and purpose of the capital alliance

- 1) As announced on December 9, 2022 in the "Notice Regarding Business Alliance with LINUS BIOTECHNOLOGY, INC.", we have signed a business alliance agreement for developing a device that automates the preparation work for sectioning and biochemical analysis of human hair, which is necessary for "Hair exposome analysis and biomarker development for precision exposome medical companies." and our company and Linus Bio are currently developing a "mounter machine (heavy metal analyzer)" and a slicer machine (organic matter analyzer).
- 2) The purpose of this capital tie-up is to promote the above development and to further strengthen and accelerate the relationship between the two companies for the future.

2. Details of the capital alliance

In this capital alliance, the following will be implemented.

- 1) We will take over the preferred stock (equivalent to 1 billion yen in Japanese yen) issued by Linus Bio. The conditions for issuance including timing and underwriting will be finalized in the future.
- 2) In conjunction with this investment, MOMOSE Takefumi, Chairman and President of the Company, will be appointed by Linus Bio as a senior technical advisor and it is expected that strengthen its influence over Linus Bio.

3. Overview of business alliance partners.

(1) Name	Linus Biotechnology, Inc. (URL : https://linusbio.com/)
(2) Address	101 6th Avenue, New York, NY, 10013, USA
(3) Name of representative & title.	CEO · Dr. Manish Arora
(4) Business content.	Linus Bio is a patient-centric, precision exposome medicine company headquartered in New York, NY. Originating from the world's leading exposome laboratory at Mount Sinai Health System, Linus has developed a technology platform that builds on breakthroughs in exposome sequencing.

(5)	Paid up capital	USD 17,357,633.00	
(6)	Establish	Mar.31, 2021.	
(7)	Major shareholders.	Icahn School of Medicine at Mt. Sinai Dr. Manish Arora Great Point Ventures Innovation Fund III, LP Bow Capital Fund II, LP Dr. Christine Austin Dr. Paul Curtin	
(8)	Relationship between the target and us.	Capital ties	Nil.
		Personal relationship	Nil.
		Business relationship	Please refer the above.
		Present relationship between the target.	Nil.

Major customer : Novozymes A/S(Kingdom of Denmark) and other confidential Pharmaceutical Company

4. Schedule

Conclusion date of investment contract May.11, 2023 (JST) scheduled.

5. Outlook

Although the impact of this matter on the Company's consolidated results for the fiscal year ending March 31, 2024 will be minor, we believe that it will contribute to the improvement of the Group's business results in the future.

In addition, depending on the progress of the capital and business alliance, we will disclose information in a timely manner if it is judged to be beneficial to shareholders and investors.

End.